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ABSTRACT
Imaging markers for monitoring disease pro-
gression in progressive multiple sclerosis (PMS)
are scarce, thereby limiting the possibility to
monitor disease evolution and to test effective
treatments in clinical trials. Advanced imaging
techniques that have the advantage of metrics
with increased sensitivity to short-term tissue
changes and increased specificity to the struc-
tural abnormalities characteristic of PMS have
recently been applied in clinical trials of PMS. In
this review, we (1) provide an overview of the
pathological features of PMS, (2) summarize the
findings of research and clinical trials con-
ducted in PMS which have applied conven-
tional and advanced magnetic resonance
imaging techniques and (3) discuss recent
advancements and future perspectives in mon-
itoring PMS with imaging techniques.
Keywords: Advanced imaging; Biomarker;
Clinical trials; Progressive multiple sclerosis
INTRODUCTION
Conventional brain imaging is increasingly
used to support clinicians in diagnosing and
monitoring the progression of multiple sclerosis
(MS) [1]. Nevertheless, the correlation between
a patient’s clinical manifestation and conven-
tional magnetic resonance imaging (MRI) mea-
sures is often weak, especially in patients with
progressive MS (PMS).
The 2013 revised classification of the clinical
phenotypes and disease course of MS catego-
rizes the disease as active or not (based on
recent clinical relapse or MRI lesion activity)
and progressive or not (based on clinical
assessment of disability), considering primary
progressive MS (PP-MS) and secondary
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progressive MS (SP-MS) to be different pheno-
types in a unique spectrum [2].
From a pathophysiologic standpoint, the
progressive stage of MS is characterized by the
segregation of inflammatory activity within the
brain compartment, where B cells play a domi-
nant role and lymphoid follicle-like structures
form in the subarachnoid space. Follicle-like
structures are observed in patients with SP-MS
but are uncommon in those with PP-MS, sug-
gesting that these two phenotypes have differ-
ent underlying pathogenetic mechanisms [3].
However, despite the absence of follicle-like
structures in the latter, meningeal inflamma-
tion and cortical demyelination are well repre-
sented in PP-MS patients also [3]. In addition to
compartmentalized inflammation, neurode-
generation is a major feature of patients with
PMS, even though the temporal relationship
between the two pathological processes remains
a matter of debate [4, 5]. At the progressive
stages of the disease, neurodegeneration seems
to occur even in the absence of an overt
inflammatory process, affecting a system
already worn out and lacking a functional
reserve [6]. Unlike in relapsing–remitting MS
(RR-MS), imaging or biological markers of dis-
ease progression and response to treatment are
scarce in PMS; consequently, there are only
limited possibilities to assess the efficacy of
treatments in clinical trials. Advanced imaging
techniques can provide important information
to improve our knowledge of MS pathophysi-
ology and to identify reliable markers of disease
progression and treatment efficacy. Indeed,
among the advanced imaging techniques, a few
have been applied in clinical trials in recent
years, in the attempt to increase their sensitivity
and identify short-term changes and treatment
response utilizing metrics that are more specific
to the structural abnormalities characteristic of
PMS [7].
In this review, we first provide an overview of
the pathological features of PMS, then we
summarize the findings of research and clinical
trials conducted in PMS which have applied
conventional and advanced MRI techniques
according to anatomical compartment (i.e.
white matter [WM], cortex, deep grey matter
[DGM], cerebellum, spinal cord). Finally, we
discuss recent advancements and future per-
spectives in monitoring PMS with imaging
techniques. This article is based on previously
conducted studies and does not contain any
studies with human participants or animals
performed by any of the authors.
WHITE MATTER DAMAGE
Pathological Features
The pathological abnormalities occurring in the
brain WM of patients with RR-MS or PMS are
similar. Both the formation and/or expansion of
focal lesions of primary demyelination in the
WM and the neurodegeneration in plaques and
normal-appearing white matter (NAWM) are
driven by inflammation and sustained by the
presence of B and T lymphocytes [6]. Focal
lesions are characterized by the formation of a
profound astrocytic scar and a variable extent of
axonal loss and remyelination, with the
prominent feature (i.e. active inflammation,
demyelination, neurodegeneration) changing
as the disease evolves [8]. In early MS, the
pathological picture is characterized by the
formation of new WM lesions, and many of the
plaques are in the active stage of demyelination.
In contrast, in PMS new active plaques are rare,
but many of the pre-existing lesions show a
slow expansion, as revealed by the presence of a
rim of activated microglia at the lesion border
associated to macrophages with inclusions of
myelin degradation products [9].
NAWM shows a profound diffuse pathology,
which consists of small perivenous inflamma-
tory infiltrates surrounded by small rims of
demyelination, diffuse astrocytic gliosis, diffuse
microglia activation and axonal degeneration
[10].
RR-MS and PMS show similar inflammation
patterns, although the global extent of lym-
phocytic inflammation is higher in RR-MS in
comparison to PMS. Indeed, in RR-MS the
lymphocytic infiltration is associated with
blood–barrier disruption, while in the progres-
sive stage, inflammation is at least partly
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compartmentalized in the brain behind an
intact blood–brain barrier [11].
Conventional Imaging
White matter lesions are usually identified on
T2-weighted (T2W) and fluid-attenuated
inversion recovery (FLAIR) sequences. Lesions
seen on T2W scans are not pathologically
specific and may show different degrees of
inflammation, axonal loss, demyelination [12]
and remyelination [13]. Thus, a cross-sectional
evaluation of a T2W lesion is a poor marker of
the underlying pathological substrate. A subset
of lesions seen on T2W and FLAIR scans can be
detected on T1-weighted (T1W) scans; these
are termed ‘‘black holes’’ due to their
hypointensity relative to the surrounding WM
and are thought to represent lesions with
greater myelin and axonal loss [14]. As persis-
tent back holes are regarded as a measure of
tissue disruption, a reduction in T1-hy-
pointense lesions accrual has been previously
used in clinical trials as an index of reduced
acute tissue damage [15].
In PP-MS, the low level of T2-visible lesion
load and gadolinium-enhancing lesions is in
contrast with the severity of the clinical fea-
tures and the steady progression of the disease
[16]. MR-detectable inflammation occurs more
commonly in early PP-MS (during the first
5 years from onset) than later in the course of
the disease [17]; however, this has been shown
to have only a minimal impact on the accu-
mulation of disability over the subsequent
5 years [18]. Similarly, the number of T2-visible
brain lesions at baseline does not seem to play
a role on the rate of clinical progression in the
subsequent 15 years in these patients [19]. In
one study in patients with SP-MS, the number
and volume of lesions at baseline showed a
number of correlations with 20 years of dis-
ability at the 20-year follow-up. The annual
rate of WM lesion accumulation was over
threefold greater in those developing SP-MS by
20 years than in patients who did not convert,
and this difference became statistically signifi-
cant after 5 years [20].
Advanced MRI Techniques
Magnetization Transfer imaging
Magnetization transfer (MT) MRI provides an
index, called the MT ratio (MTR), whose values
reflect the efficiency of the magnetization
exchange between protons in tissue water and
those bound to the macromolecules. Post-mor-
tem studies [13, 21] have shown that marked
reductions in MTR values in MS lesions and
NAWM are strongly correlated with the percent-
age of residual axons and the degree of demyeli-
nation and that MTR values of remyelinated
lesions are higher than those of the NAWM.
MTR values of T2-visible lesions are
decreased relative to those of the NAWM in PP-
MS patients, and MTR values of the NAWM are
decreased relative to those of the WM of healthy
controls [22, 23]. Damage to the NAWM is more
pronounced in SP-MS and PP-MS patients than
in other clinical phenotypes [24, 25], but it does
not differ between patients with the two pro-
gressive forms of the disease [26]. Longitudinal
studies suggest that MT MRI has the potential to
be a good biomarker of progression in PP-MS: in
patients with early PP-MS, lower NAWM MTR
values at baseline predict a more severe deteri-
oration of disability over 1 [27] and 3 years [28].
In view of these findings, MTR has been inclu-
ded in several clinical trials of PMS [29–31]. In
an open-label phase 2A study on the use of
natalizumab for treating patients with SP-MS,
MTR was used to assess the tissue integrity on a
macromolecular level. In the treated patients,
MTR values increased in NAWM, indicating an
increased integrity of myelin and neurons or
reduced microglial activation [31]. In a study on
the use of autologous mesenchymal stem cells
in SP-MS patients, the MTR increased after
treatment, but these changes were not statisti-
cally significant [29]. In a longitudinal study in
SP-MS patients treated with interferon (IFN)
beta-1b, there was a decrease in the average
brain MTR values from baseline to month 24
and month 36. These changes were significant
for the placebo group at both time points and
for the IFN beta-1b group at month 24 only,
with no significant treatment effect [32].
Another longitudinal study investigated the
role of lamotrigine in SP-MS and demonstrated
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a decrease in the NAWM MTR in the treated
patients at baseline, but no differences in MTR
change between the two groups at follow-up
[33]. In summary, MT MRI provides informa-
tion on the changes which occur in both
NAWM and WM lesions, and it is sensitive to
disease changes over time [34]. Furthermore,
values derived from MT MRI are reproducible
[35] and relatively cost-effective.
Diffusion Tensor Imaging
Diffusion tensor imaging (DTI) is a diffusion-
weighted MRI method that measures brain tis-
sue microstructure exploiting the properties of
water diffusion. Using the measures obtained
with this method, it is possible to calculate the
magnitude of diffusion, reflected by mean dif-
fusivity (MD), diffusion anisotropy, which is a
measure of tissue organization, generally
expressed as fractional anisotropy (FA), axial
diffusivity (AD) and radial diffusivity (RD), with
the latter two items being measures of axonal
integrity and myelin integrity, respectively
(Fig. 1) [36].
The FA within T2 lesions is usually decreased
and the MD usually increased in comparison
with those of the surrounding NAWM [37]. An
overlap between MD and FA maps and T2 lesion
distribution has been demonstrated in most MS
phenotypes [38], with the exception of PP-MS
patients, in whom there is a discrepancy
between regional WM diffusivity changes and
T2-visible focal lesions [39]. The absence of any
overlap in PP-MS between FA maps and T2
lesions [38] support the hypothesis that axonal
damage and T2 lesions are partially
independent.
WM diffusion abnormalities are more pro-
nounced in patients with SP-MS than in those
with RR-MS [38, 40]. The greater increase in
diffusivity in SP-MS than in other phenotypes is
presumably caused by a combination of axonal
loss and tissue destruction processes with
inflammatory events [40]. The high degree of
axonal degeneration in such patients is con-
firmed by the widespread decrease in FA, not
only within lesions but also in the NAWM [38].
Although widespread diffusivity changes
have been detected in patients with PP-MS in
comparison with healthy controls, with increa-
ses in MD, RD and AD and decreases in FA
[38, 41], the NAWM is affected to a lesser degree
in PP-MS patients than in SP-MS patients
[38, 42], probably owing to the more pro-
nounced inflammation present in SP-MS than
in PP-MS. Diffusion-based MRI parameters have
been used to assess the role of natalizumab in
SP-MS, with the results revealing a significant
increase in FA in the NAWM and in AD and RD
in T2 lesions after 60 weeks of treatment [31].
DTI measures have also been applied in
monitoring tissue integrity in ongoing clinical
trials evaluating the efficacy of ibudilast and
fluoxetine in progressive MS [30, 43].
Fig. 1 Three-dimensional T1-weighted image (a) and representative maps of fractional anisotropy (b) and mean diffusivity
(c) from a patient with progressive multiple sclerosis
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However, although sensitive to changes in
tissue integrity, classical DTI metrics may lack
pathological specificity. Additionally, the sam-
ple size estimates for diffusion-based metrics are
highly variable and depend on the specific
metric and the area of the brain [44].
Proton Magnetic Resonance Spectroscopy
Proton magnetic resonance spectroscopy (1H-
MRS) can quantify the brain levels of several
metabolites [45]. The most commonly mea-
sured neurometabolite is total N-acetyl-aspar-
tate (NAA), a marker of axonal loss and
metabolic dysfunction [46]. NAA levels are sig-
nificantly decreased in the NAWM of PP-MS
patients relative to the WM of healthy controls,
but comparisons of 1H-MRS findings between
patients with PP-MS and those with other dis-
ease phenotypes does not show significant
between-group differences in terms of lesional
and NAWM levels of NAA [47, 48]. The ratio
between NAA and other metabolites has been
used in a clinical trial to compare glatiramer
acetate-treated and placebo-treated PP-MS
patients; no differences in the NAWM and WM
lesions of the two groups [49].
Positron Emission Tomography
Positron emission tomography (PET) is a
quantitative imaging technique which inves-
tigates cellular and molecular processes in vivo
using a positron-emitting radionuclide (tracer).
Many radiotracers can be used in PET,
including the selective radioligand 11C-
PK11195 that expresses the concentration of
translocator protein (TSPO) [50], a protein that
is upregulated in activated microglia [51].
Studies on PMS have demonstrated an
increase in TSPO uptake in the NAWM that
appears to be related to clinical severity and
patient age [52]. TSPO binding is significantly
increased in the NAWM of SP-MS patients in
comparison to the NAWM of healthy controls,
with this increase being a demonstration of
persisting inflammatory activity [53]. To date,
no large MS clinical trials have included PET,
reflecting its relatively invasive nature and
high costs.
CORTICAL DAMAGE
Pathological Features
Although no pathognomonic MRI parameter
has been identified in PMS, some of the char-
acteristics highlighted by histopathology stud-
ies, such as higher grey matter (GM) atrophy,
larger cortical demyelination and meningeal
inflammatory aggregates, can be imaged with
specific advanced MRI techniques. Inflamma-
tion, the prominent feature of MS in the early
stages, persists in PMS but becomes compart-
mentalized within the central nervous system,
behind an intact blood–brain barrier. Although
a mild disruption of the blood–brain barrier has
been reported in the context of chronic lesions,
inflammatory infiltrates displaying structural
features of lymphatic follicles tend to localize in
the connective tissue spaces of the brain, such
as the meninges and the large Virchow–Robin
spaces [54]. Leptomeningeal infiltrates are often
associated with cortical lesions, which are most
abundant in the progressive stage of MS and
involve preferentially the subpial cortical layers
[10]. Beyond focal lesions, demyelination
extensively involves GM in PMS, and the cortex
is regarded as a primary site of neurodegenera-
tion as brain atrophy in PMS is mainly related to
extensive loss of synapses and the focal loss of
neuronal bodies in the cortex [55, 56], rather
than WM loss [57].
Advanced MRI Techniques
Post-Contrast FLAIR
Leptomeningeal inflammatory infiltrates can be
visualized with delayed high-resolution post-
contrast T2 FLAIR MRI [58, 59]. Such infiltrates
are closely associated with subpial demyelina-
tion and cortical atrophy, show a high preva-
lence in progressive patients (33% in SP-MS vs.
19% in RR-MS) and tend to remain stable over
time [58–60]. They are not exclusively observed
in MS, but their relationship with cortical atro-
phy and cortical lesions appears to be highly
specific [61].
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Double Inversion Recovery and Phase-Sensitive
Inversion Recovery
Grey matter demyelination is more frequent in
patients with PMS than in those with RR-MS
[10]. Cortical lesions can be visualized, at 1.5
and 3.0 Tesla, with specific sequences that
enhance the contrast between normal-appear-
ing GM and focal GM lesions. Both double
inversion recovery (DIR) and phase-sensitive
inversion recovery (PSIR) can be used to detect
MS cortical pathology, with PSIR showing the
higher sensitivity [62]. At an ultra-high MR field
(7 Tesla), cortical lesions can be imaged through
FLASH-T2*, and lesions so identified show a
strong correlation with disability status [63].
Although no clinical trial has applied cortical
lesion quantification in PMS, suppression of
cortical pathology (i.e. cortical lesion accumu-
lation and cortical atrophy progression) has
been reported in a longitudinal study exploring
the impact of natalizumab antinflammatory
activity in RR-MS [64].
Magnetization Transfer Ratio
Demyelination involves not only WM but also
cortical GM, with myelin repair appearing to be
more efficient in lesions in the latter than in
those in the former [65]. MTR maps are sensitive
to changes in myelin content in all brain tissues
[66], and although the MTR signal can be
influenced by factors such as axonal loss,
inflammation and edema, their impact is less
pronounced in the cortex [67], supporting the
suitability of MTR for investigating myelin loss
and repair in cortical areas. The MTR shows a
high correlation with myelin and axonal con-
tent in post-mortem MS samples [21, 68] and
with NAA, which is a spectroscopic marker of
neuroaxonal content in vivo [69]; as such, it is
particularly promising as imaging marker in
PMS where axonal loss and GM damage are
prominent. Normal-appearing GM (NAGM)
demyelination, as measured using the MTR, has
been chosen as the imaging outcome in several
trials conducted in PMS and found to demon-
strate a good correlation with clinical disability
and sensitivity to treatment effects
[27, 31, 33, 70]. Unfortunately, despite showing
a consistently good correlation with disability
metrics, responsiveness of the MTR to change
(i.e. the longitudinal correlation of MTR mea-
sures with sustained disability), which was
specifically evaluated in a randomized placebo
controlled trial of lamotrigine in SP-MS, seems
to be limited [33].
Diffusion Tensor Imaging
Different degrees of NAGM damage can be
identified via diffusion-weighted imaging and
DTI in different MS phenotypes, with more
severe changes reported in PMS that RR-MS
[42, 71]. In patients with progressive disease,
DTI-derived parameters are also able to detect
significant worsening over 1 year of follow-up,
with NAGM damage occurring independently
from T2 lesions and brain atrophy accrual
[42, 72]. DTI-derived metrics are sensitive to
change over time [31] and reproducible across
different centers [73, 74]. However, the ade-
quacy of these metrics in describing the com-
plexity of brain tissue has been questioned in
recent years, as the DTI model assumes that
each voxel contains a single tissue compart-
ment with Gaussian diffusion and that its met-
rics are affected similarly by changes in
microstructure and changes in directional
organization. As a consequence, multi-com-
partment models have been developed to take
into account the complexity of brain tissue
microstructure [75] in an attempt to better
characterize pathophysiological processes
underlying tissue damage.
T2*
T2* relaxation time is a quantitative measure of
myelin and iron content [76]. In cortical
lesions, correlation studies of histopathological
and MR data have shown that demyelination
and iron loss induce an increase in T2* relax-
ation time [77, 78], while iron accumulation
results in a shorter T2* [79]. At ultra-high field,
surface-based mapping of quantitative T2* is a
non-invasive tool to assess in vivo the archi-
tecture of the cortex, as it offers the possibility
to conduct a laminar analysis as a function of
the cortical depth [80]. The application of this
method has shown a gradient of cortical
pathology, with superficial cortical layers
involved in early stages and deeper cortical
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layers involved in later disease stages, thereby
supporting the presence of a pathological
mechanism driven from the pial surface [81].
Proton Magnetic Resonance Spectroscopy
1H-MRS allows the quantification of NAA,
which is synthesized by neuronal mitochon-
dria, offering the possibility to monitor neu-
roaxonal dysfunction and quantify diffuse GM
involvement. Several studies have demon-
strated a decrease in NAA in the cortical GM of
patients with PMS [41, 82], but the clinical
translation of 1H-MRS-derived parameters is
hampered by the negative results of several
longitudinal studies [49, 83].
Positron Emission Tomography
Positron emission tomography with TSPO radi-
oligands allow in vivo imaging of microglial
activation and has proven the persistence of
widespread inflammation in cortex and cortical
lesions in PMS [52]. Such microglial activation
seems to have a pathological role and to be
clinically meaningful, as it is related to cortical
thinning and clinical disability [52].
T1-Derived Measures of Atrophy
Quantitative estimation of brain atrophy, based
on T1W sequences, suggests that progressive
loss of brain volume is driven by GM atrophy
[84]. Global cortical atrophy is more prominent
in PMS than in the other disease phenotypes,
and it is associated with both the motor and
cognitive components of clinical disability in
cross-sectional and longitudinal studies
[20, 57, 84]. More recently, a regional analysis of
cortical atrophy rate has demonstrated that
atrophy does not follow the same spatiotem-
poral pattern in all MS phenotypes and that
temporal cortical GM shows accelerated atro-
phy in SP forms [85]. Sample sizes for brain
atrophy outcomes in PMS clinical trials have
demonstrated that longitudinal estimation of
brain volume changes through a registration-
based method has a higher sensitivity than
segmentation-based techniques, highlighting
the fact that the sensitivity of imaging
biomarkers is strictly dependent on the selected
processing pipeline [86]. Brain atrophy and GM
atrophy have been used as primary outcomes in
several phase 2 and phase 3 clinical trials in PMS
[30, 87–89]; both were found to show a good
effect size in the treatment arm in comparison
to the placebo arm. Conversely, the application
of cortical atrophy measurement (i.e. cortical
thickness) in clinical trials is limited by the
computational efforts required for its estima-
tion. Taking into account that regional volumes
show higher sensitivity to change over time
than whole brain volume and that atrophy
development follows different patterns across
phenotypes, future trials should focus on the
selection of sensitive and specific outcome
measures that consider the characteristics of the
target population.
SPINAL CORD
Pathological Features
In MS patients, spinal cord lesions are fre-
quently detected in the upper cervical cord, but
diffuse abnormalities of the spinal cord can also
be observed that are associated with demyeli-
nation and axonal loss. Not only WM
demyelination, which involves in particular the
cervical tract, but also extensive demyelination
of the spinal cord GM has been detected, in
post-mortem studies [90]. Performing a post-
mortem in situ spinal cord MRI, Bergers et al.
found that signal intensity on proton density-
weighted images inversely correlated with
histopathologically detected myelination in
PMS [91]. In another study involving 19
patients with either SP-MS or PP-MS, a good
correlation between the MR signal and
demyelination based on histopathology was
reported [92]. Moreover, a reduction in axonal
density both at the level of the plaque and the
NAWM has been described in SP patients [93].
Neuronal loss is detected primarily in the local
GM plaques and interneurons in both myeli-
nated and demyelinated areas [95]. However,
myelin content and axonal loss can occur
independently, and MR signal intensity abnor-
malities strongly correlate with demyelination
[94]. There are no differences between PP-MS
and SP-MS patients in terms of the presence of
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inflammatory demyelination and the capacity
of remyelination at the level of the spinal cord,
although some differences can be detected at
the level of the brain between the two groups
[96].
Conventional Imaging
Spinal cord imaging is performed less frequently
than brain imaging in patients with MS. Several
factors can affect the imaging quality, resulting
in artifacts, such as the small dimensions of the
spinal cord, the surrounding structures (i.e.
bone, fat and cerebrospinal fluid [CSF]), which
create magnetic field inhomogeneities, and
physiological movements (CSF pulsation, car-
diac and respiratory rhythmic motions), Still,
spinal cord imaging is crucial to the diagnosis
and prognosis of the disease, and guidelines for
a recommended MR spinal cord protocol have
been published [97, 98].
In patients with MS, the cervical tract of the
spinal cord has a greater lesion load than do
other tracts [99], and it is the most commonly
studied tract. In the first study quantifying the
cervical spinal cord lesion load in different
clinical subtypes, the authors found a signifi-
cantly higher lesion load in both SP-MS and PP-
MS patients than in RR-MS patients, with the
higher load associated with clinical disability
[100].
A spinal cord syndrome is the most common
onset in patients with PP-MS [101] and, in the
most recent revised 2017 McDonald criteria, the
presence of lesions in the spinal cord is con-
firmed among the MR criteria for dissemination
in space and for the diagnosis of PP-MS [1].
Moreover, the number of spinal cord lesions has
been found to predict conversion from radio-
logically isolated syndrome (RIS) to PP-MS [102].
Advanced MRI Techniques
Magnetization Transfer Ratio
Magnetization transfer ratio abnormalities in
the pial and subpial regions of the spinal cord
are more marked in patients with PMS com-
pared to the early stages, hinting at subpial
demyelination as the underlying pathological
process, possibly related to meningeal inflam-
mation [103]. In a MTR study of PP-MS and SP-
MS patients, the two groups showed a compa-
rable diffuse damage of the cervical spinal cord,
although the latter group presented the greater
lesion burden [26].
Diffusion Tensor Imaging
Although advanced techniques and analytical
models for the application of DTI metrics to the
spinal cord represent an active research field, a
unified method of analysis has not been defined
to date, and the potential use of DTI metrics in
clinical trials is still far from practical imple-
mentation [104].
Similar to what has been found for the vol-
umetric measures, no relationship between DTI
metrics of the brain and those of the spinal cord
has been found in PP-MS patients. However, in
one study reduced FA and higher MD content at
the level of the cervical spinal cord were found
in the patient group relative to healthy controls
[105].
MD and RD at the level of the posterior col-
umns have been found to be significantly
higher in SP-MS patients than in patients with
RR-MS. Moreover, FA, MD and RD of the spinal
cord GM have also been found more altered in
SP-MS patients than in those with RR-MS or
clinically isolated syndrome (CIS), and GM RD
is also correlated with clinical disability [103].
In a longitudinal diffusion MR study on RR-
MS, SP-MS and PP-MS patients, over a mean
follow-up of 2.4 years, the decrease in FA of the
cervical segment was reported to be higher in
patients with PP-MS. However, the worsening in
DTI metrics did not correlate with supratento-
rial damage or with the extent of the local
lesion load [106].
T1-Derived Measures of Atrophy
Several different methods are currently avail-
able to evaluate cervical spinal cord atrophy in
patients with MS, including the measurement
of the cross-sectional area at several anatomical
levels or measurment of the volume between
two levels (Fig. 2) [107, 108].
Diffuse axonal degeneration is more respon-
sible than local inflammatory lesions for spinal
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cord atrophy [109]. Spinal cord atrophy is present
from the early stages of MS onwards, is faster in
patients with disease progression [110] and is
predictive of disability. In two studies, patients
with PMS presented a higher lesion load and
atrophy at both the cervical and thoracic levels
than did patients with RR-MS [100, 111]; addi-
tionally, the spinal cord area at both levels, in
particular that of the GM, was found to correlate
with clinical disability [111]. Although the area
of the upper cervical segments is the preferred
area of study, Zeydan and colleagues observed
that the C7 area presented the greatest difference
between patients with RR-MS and those with SP-
MS at the early disease stages [112]. In their study
involving 26 PP-MS patients, Ruggieri et al.
found a smaller cervical spinal cord volume (at
both the C2–C3 and C2–C5 levels) in their
patients compared to the healthy controls, but
spinal cord atrophy did not correlate with brain
lesion load or volume [16].
In a longitudinal study of PP-MS patients
with a radiological follow-up of 15 months,
Rocca and colleagues acquired brain and spinal
cord tissue and detected a significant decrease
in cervical cord cross-sectional area [113]. In a
cohort of 56 SP-MS patients, Furby and col-
leagues found that the spinal cord cross-sec-
tional area presented the highest annual rate of
atrophy among other MRI measures and corre-
lated with changes in the Multiple Sclerosis
Functional Composite (MSFC) measure [114].
Finally, Cawley et al. studied a population of
PMS, and at the 1-year follow-up they found
that the spinal cord cross-sectional area was
significantly reduced in PP-MS patients, but not
in SP-MS patients, when compared to healthy
controls. Moreover, they calculated that the
sample size for a 12-month neuroprotective
clinical trials in PP-MS patients which would be
required to observe a treatment effect of 50%
would have been 57 subjects per arm, leading
the authors to conclude that spinal cord atro-
phy could be used as an outcome measure in
clinical trials [115]. In this study, the authors
used the active surface model method to assess
changes in cross-sectional area, a method which
has been proved to be reliable and have good
reproducibility [103].
Indeed, the role of spinal cord atrophy as an
outcome measure has been assessed in a few
clinical trials of patients with PMS. In a phase II
study assessing the safety and efficacy of IFN
beta-1b versus placebo in 70 patients with PP-
MS, Montalban et al. found no differences in
the cervical spinal cord area between the two
arms [116]. In another exploratory trial in PP-
MS patients, this time testing the efficacy of IFN
beta-1a versus placebo, Leary et al. [117] again
found no differences in the spinal cord mea-
sures (number of lesions and atrophy) between
the two groups. Finally, no differences in cer-
vical spinal cord area were found in a trial
testing the neuroprotective effects of lamotrig-
ine versus placebo in SP-MS patients [88].
It is possible to introduce spinal cord damage
as an end-point measure in clinical trials in
patients with PMS, in particular in the PP-MS
group. However, a standardized approach with
specific MR protocols, including high-resolu-
tion images for a precise detection of lesion load
and the choice of a reproducible and a reliable
method to calculate atrophy in longitudinal
evaluation, are recommended.
Fig. 2 Example of spinal cord volume measurement on a
three-dimensional (3D) T1-weighted image from a patient
with progressive multiple sclerosis (PMS) (Jim, ver. 6).
a Using the inferior border of C5 as a reference, a marker
was placed at this level and then, moving back from C5, a
marker was set every 10 slices until the ﬁrst marker at C2
was reached (b), with the ﬁnal output with the outlined
cord shown
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CEREBELLUM
Pathological Features
The cerebellum is a predilection site for
demyelination in patients with MS [118], with
the cerebellar cortex in particular having been
shown to be more demyelinated than the cor-
tical regions of the forebrain. This cortical
demyelination occurs even in absence of WM
damage.
A post-mortem study of PMS patients found
a higher rate of cortical demyelination at the
level of the cerebellum and spinal cord [90]. The
pathology of Purkinje cells, which are respon-
sible for the output signal from the cerebellum,
have also been described within areas of cortical
demyelination [119]. Meningeal inflammation
has been detected in SP-MS patients at the level
of the cerebellum and in association with cor-
tical demyelination and found to be indepen-
dent of the presence of follicle-like structures
[120].
Advanced MRI Techniques
Diffusion Tensor Imaging
Reduced FA and increased RD values at the level
of the middle cerebellar peduncle have been
reported in patients with PP-MS in comparison
to both the healthy controls and RR-MS
patients; the abnormality of the DT metrics was
clinically eloquent in terms of disability of the
upper and lower limbs [121].
T1-Derived Measures of Atrophy
Cerebellar cortical volume loss has been detec-
ted in MS patients at all stages of the disease,
from the very early stage onwards [122].
Although several technical difficulties ham-
per the reliability of cerebellar volume mea-
surement, a number of automated and semi-
automated image analysis methods have been
developed and implemented in recent years
(Fig. 3). In one study, cerebellar GM volume was
found to be reduced in SP-MS patients com-
pared to healthy controls [123]. In another
study, atrophy of specific cerebellar lobules in
PMS patients correlated with clinical disability,
as assessed by means of 9-hole-peg-test and
cognitive tests [124].
Longitudinal observations in PP-MS patients
demonstrated a higher rate of atrophy in the
cerebellar cortex over 5 years in comparison
with healthy controls [125]; there was also a
greater volume loss in patients, showing disease
progression [126]. These observations suggest a
potential role for cerebellar volume as an
imaging outcome in clinical trials. In this study,
the sample size necessary to consider cerebellar
volume as a possible outcome was found to be
Fig. 3 Example of cerebellar segmentation on a 3D T1-weighted image from a patient with PMS. Middle image: the
isolated cerebellar grey matter obtained by SUIT (spatially unbiased infratentorial toolbox), shown in red, is superimposed
to the T1-weighted image. Right image: the SUIT cerebellar atlas aligned in the native subject space. Reproduced from
Cocozza et al. [124]
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relatively small and thus easily applicable in
clinical trials.
DEEP GREY MATTER
Pathological Features
The pathology of DGM in MS is characterized
by the presence of focal lesions and atrophy and
by increased iron content in both RR-MS and
PMS patients. Demyelination of DGM nuclei is
also a pathological hallmark of the disease.
Demyelinating lesions are more often observed
at the level of the thalamus and caudate; they
involve both GM and WM and show an
immunopathological pattern similar to the WM
lesions but with lower degree of inflammation
and axonal damage [127, 128].
Advanced MRI Techniques
Susceptibility Weighted Imaging
Reports of iron content in the DGM and in
particular in the DGM nuclei of PMS patients
are conflicting. Using R2* mapping, Ropele et al.
reported increased DGM iron levels in a group
of RR-MS, SP-MS and PP-MS patients compared
to healthy controls, although the thalamus was
not included as a region of interest, and the
result was primarily driven by the RR-MS group
[129]. In PP-MS patients, iron content in the
putamen has been found to be positively asso-
ciated with the Expanded Disability Status Scale
(EDSS) score [130]. A comparison of iron con-
centration across phenotypes revealed a pro-
gressive accumulation of iron in the DGM
through the different MS stages [131].
However, a recent study using quantitative
susceptibility maps has reported reduced iron
content in the thalamus of RR-MS and SP-MS
patients, with this reduction being significantly
associated with disease duration [132]. The
authors of this study advanced the hypothesis
that iron loss associated with disease progres-
sion could be explained by the loss of oligo-
dendrocytes, since these cells and their
processes contain most of the iron in the WM
and DGM in the brain [132].
T1-Derived Measures of Atrophy
In patients with PP-MS, atrophy of the thalami
is detected in the first years of the disease
[125, 133], and the thalamic volume has been
found to be correlated with global and frontal
lobe cortical lesion load [16]. These findings are
supported by a study combining histopatho-
logical and MR techniques that found an asso-
ciation between thalamic cell density and
volume loss of the corresponding cortical areas
[134].
Very few studies have evaluated longitudinal
changes in DGM volume in PMS patients. Sev-
eral drawbacks are encountered when dealing
with both global and local volume measure-
ments. Specifically, in studies on DGM, the
availability of different software for analysing
segmentation and the choice of different sta-
tistical methods have resulted in inconsistent
results across different studies. Similar to cross-
sectional studies, in longitudinal studies
sequence parameters, image resolution, quality
and head positioning can affect the output
[135]. Mesaros et al. described increased thala-
mic atrophy in patients with PP-MS compared
to healthy controls at a follow-up of 15 months.
In a study of different MS clinical subtypes (CIS,
RR-MS and SP-MS), with an average follow-up of
4.1 years, Azevedo et al. reported that thalamic
volume loss was higher in patients than in
healthy controls but that this volume loss was
consistent across the different MS subtypes
[136]. Conversely, the study of Eshaghi et al.,
with a larger patient sample that included all
MS phenotypes and an average follow-up of
2.4 years, found that the DGM atrophy rate was
higher in patients with PMS (both SP-MS and
PP-MS) than in those with CIS and healthy
controls [85]. Moreover, thalamus volume at
baseline was predictive of disability progression
at follow-up. In a 24-month study including
patients with CIS, RR-MS and SP-MS, the sample
size needed to detect significant changes was to
be 80–100 subjects per arm, thus supporting the
measure of thalamic volume as an MRI end-
point in clinical trials of neuroprotective agents
[136].
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Table 1 Application of imaging techniques for the monitoring of disease progression
Techniquea Findingsb Limitations Evidence of application
for disease progression
monitoring
T2W and
FLAIR
sequences
Brain WM:
PP-MS: T2-LL at baseline did not predict the rate of
clinical progression at 15 years FU [19]
SP-MS: T2-LL at baseline correlated with disability at
20 years FU. The annual rate of WM lesion
accumulation was higher in patients developing SP-
MS [20]
Detection of exclusive macroscopic damage.
Not a good correlation between lesion aspects
and pathological ﬁndings
Present
Spinal cord:
PMS: cervical spinal cord lesion load was higher
compared to RR-MS, and related to clinical
disability [100]
PP-MS: the presence of spinal cord lesions predicted
conversion from RIS to PP-MS [102]
Post-contrast
FLAIR
Cortex:
SP-MS: leptomengingeal inﬁltrates were more
frequent compared to RR-MS and tended to remain
stable over time [58–60]
Absent
T1W sequences Cortex:
PMS: global cortical atrophy was more prominent
compared to other ClPh and was related to motor
and cognitive impairment [20, 57, 84]
SP-MS: temporal cortical atrophy was accelerated [85]
Need of standardized protocols including high
resolution images.
The need of a reproducible and reliable method
to quantify atrophy
Present
Whole brain, GM and
spinal cord atrophy have
been used in clinical trials
[30, 87–89, 116, 117]
Spinal cord:
PMS: higher cervical and thoracic spinal cord atrophy
compared to RR-MS and it correlated to clinical
disability [100, 111]
PP-MS: cervical spinal cord atrophy did not correlate
with brain lesion or volume [16]
SP-MS: cross-sectional area at the level of C7
presented the greatest difference compared to RR-
MS [112]
Results of longitudinal studies were discordant (see
text)
Cerebellum:
PP-MS: higher rate of atrophy compared to HC over
5 years, with greater volume loss in patients with
disease progression [125, 126]
SP-MS: GM volume was reduced compared to HC
and atrophy of speciﬁc lobules correlate with clinical
disability [123, 124]
DGM:
PP-MS: atrophy of the thalami was detected since the
early years and correlate with global and frontal lobe
lesion load [16, 125, 133]
Longitudinal studies gave discordant results across
different ClPh (see text)
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Table 1 continued
Techniquea Findingsb Limitations Evidence of application
for disease progression
monitoring
MT imaging Brain WM:
PMS: NAWM damage assessed by MTR was higher
compared to other ClPh but did not differ between
SP and PP-MS [24, 25]
PP-MS: MTR values of NAWM were lower
compared to HC. MTR values of the lesions were
decreased compared to NAWM. Lower NAWM
MTR values at baseline predicted a more severe
disability progression [22, 23, 27, 28]
MTR could be inﬂuenced by several factors
(axonal loss, inﬂammation, edema)
MTR responsiveness to changes seems to be
limited
Present
MTR has been used in
clinical trials [29–31]
Cortex:
PMS: demyelination at the level of the normal
appearing GM, assessed by MTR, correlated with
clinical disability and was sensitive to treatment
effects [27, 31, 33, 70]
Spinal cord:
PMS: damage assessed by MTR was more pronounced
in the pial and subpial regions compared to other
ClPh. Damage was comparable between PP- and SP-
MS patients [26, 103]
DTI Brain WM:
PMS: NAWM damage, assessed by diffusion imaging,
was less affected in PP-MS compared to SP-MS
[38, 42]
PP-MS: DTI metrics were altered compared to HC.
No overlap between diffusivity and T2 lesion maps
suggests axonal damage and focal lesions are
independent processes [38, 41]
SP-MS: diffusion abnormalities were more
pronounced compared to RR-MS [38, 40]
Lack of pathological speciﬁcity
Need of variable sample size depending on the
speciﬁc metric and area of the brain.
The need to use advanced models to better
describe the complexity of brain tissue and to
characterize different pathological processes
Present
Diffusion based MRI
parameters have been
used in clinical trials
[30, 31, 43]
Cortex:
PMS: changes in DTI metrics were more severe
compared to RR-MS. DTI parameters could detect
increased damage over 1 year, not correlated with T2
lesion load and brain atrophy [42, 71, 72]
Spinal cord:
PMS: among PP, SP and RR patients the former had
the most marked decrease of FA values in the
cervical segment over a mean of 2.4 years FU [106]
PP-MS: DTI metrics were altered compared to HC
[105]
SP-MS: DTI metrics were altered both at the level of
the posterior columns and GM of the spinal cord
compared to RR-MS patients. GM RD correlated
with disability [103]
Cerebellum:
PP-MS: altered DTI metrics at the level of the middle
cerebellar peduncle compared to HC and RR-MS.
They correlated with clinical disability [121]
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RECENT ADVANCEMENTS
AND FUTURE PERSPECTIVES
One of the barriers to assessing potential neu-
roprotective agents in MS is the slow rate of
disability accrual. Thus, clinical disability out-
come measures exhibit a poor sensitivity when
applied to small groups of patients over rela-
tively short periods of time. MRI surrogates are
more sensitive to disease activity, and current
MRI measures of tissue inflammation, such as
gadolinium-enhancing and new T2 lesion
count, are useful to monitor response to antin-
flammatory agents in patients with RR-MS. MRI
measures of inflammation, however, are insen-
sitive markers in patients with PMS since the
underlying pathology is dominated by diffuse
damage to brain GM and WM and a worsening
of tissue damage within existing lesions rather
than by the accumulation of new brain WM
lesions. Nonetheless, a role for MRI measures of
active inflammation has been recently
acknowledged in PMS patients with an ongoing
inflammatory process [137], highlighting the
importance of selecting pertinent outcomes in
relation to the characteristics of the investigated
population when designing clinical trial
(Table 1).
Table 1 continued
Techniquea Findingsb Limitations Evidence of application
for disease progression
monitoring
MR
spectroscopy
Brain WM:
PP-MS: NAA of NAWM was found lower compared
to HC but not when compared to other ClPh
[47, 48]
Absent
MR spectroscopy has been
used in clinical trials [49]
Cortex:
PMS: A NAA decrease has been found in the cortical
GM [41, 82].
Longitudinal studies gave negative results [49, 83]
PET with
TSPO
Brain WM:
PMS: increased uptake in NAWM, related to clinical
severity and patient age [52]
SP-MS: the uptake was increased in NAWM
compared to HC suggesting persisting inﬂammation
[53]
Invasive and expensive tool Absent
Cortex:
PMS: persistent cortical inﬂammation at the level of
the cortex and cortical lesions, related to clinical
disability [52]
SWI/T2* Cortex:
PMS: a gradient of cortical pathology has been
showed, with superﬁcial layers involved early
compared to deeper ones [81]
Absent
DGM:
PMS: studies on the iron content at the level of DGM
gave discordant results (see text)
a T1W/T2W T1/T2-weighted, FLAIR ﬂuid-attenuated inversion recovery, MT magnetization transfer, DTI diffusion tensor imaging, MR magnetic
resonance, PET positron-emission tomography, TSPO translocator protein, SWI susceptibility-weighted imaging
b WM White matter, PP-MS primary progressive multiple sclerosis, RIS radiologically isolated syndrome SP-MS secondary progressive multiple sclerosis,
RR-MS relapsing–remitting multiple sclerosis, PMS progressive multiple sclerosis, T2-LL T2-lesion load, FU follow-up, DGM deep grey matter, NAWM
normal-appearing white matter, HC healthy controls, GM grey matter, MTR magnetization transfer ratio, NAA N-acetyl-aspartate, ClPh clinical phe-
notypes, RD radial diffusivity, FA fractional anisotropy
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CONCLUSION
The ideal neuroimaging biomarker for PMS
monitoring should offer high specificity for the
pathophysiological mechanisms underlying
tissue damage, be sensitive to change over a
short time period and be reproducible across
multiple sites, with the aim to facilitate stan-
dardization and application in multicentre
clinical trials. Although much progress has been
made in terms of developing more specific MRI
markers, only a few longitudinal studies have
explored the sensitivity of these markers over
time due to the technical challenges related to
standardization of advanced imaging protocols
and post-processing techniques. Among the
available markers, brain atrophy seems the
closest option to bridge the gap between
research and clinical application, with DGM
volume and the cerebellum showing a high
sensitivity among the regional metrics [85, 126],
while other advanced techniques characterizing
tissue microstructure should be selected for
exploratory trials to answer specific questions
about drug efficacy in neuroprotection and tis-
sue repair. In particular, MTR-based imaging or
multi-compartment diffusion imaging might be
useful to investigate the effect of drugs pro-
moting remyelination, while post-contrast
FLAIR could be applied to investigate the
monitoring response to drugs targeting B cells.
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